LON:AZN), 14 rate it a "Buy", 4 "Sell", while 12 "Hold".">

Were Analysts Bearish AstraZeneca plc (LON:AZN) This Week?


Out of 30 analysts covering AstraZeneca PLC (LON:AZN), 14 rate it a “Buy”, 4 “Sell”, while 12 “Hold”. This means 47% are positive. AstraZeneca PLC has been the topic of 256 analyst reports since September 17, 2015 according to StockzIntelligence Inc. Below is a list of AstraZeneca plc (LON:AZN) latest ratings and price target changes.

13/09/2016 Broker: Liberum Capital Rating: Hold New Target: GBX 5200.00 Reinitiate
12/09/2016 Broker: Jefferies Rating: Buy Old Target: GBX 5400.00 New Target: GBX 5800.00 Upgrade
08/09/2016 Broker: Berenberg Rating: Buy New Target: GBX 5550.00 Maintain
08/09/2016 Broker: Deutsche Bank Rating: Buy Maintain
06/09/2016 Broker: JP Morgan Rating: Neutral Maintain
06/09/2016 Broker: Deutsche Bank Rating: Buy Old Target: GBX 5800.00 New Target: GBX 5800.00 Maintain
05/09/2016 Broker: Shore Capital Rating: Hold Maintain
01/09/2016 Broker: Shore Capital Rating: Hold Maintain
25/08/2016 Broker: Beaufort Securities Rating: Hold Maintain
24/08/2016 Broker: Shore Capital Rating: Hold Maintain

The stock increased 0.71% or GBX 34.35 on September 13, hitting GBX 4892.35. About 2.73M shares traded hands or 10.08% up from the average. AstraZeneca plc (LON:AZN) has risen 21.72% since February 11, 2016 and is uptrending. It has outperformed by 5.24% the S&P500.

AstraZeneca PLC is a biopharmaceutical company. The company has a market cap of 61.56 billion GBP. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. It has a 37.15 P/E ratio. The Firm has its activities in over 100 countries.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply